Aug 20, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Is Climb Bio, Inc. ( CLYM ) Outperforming Other Medical Stocks This Year?
Here is how Climb Bio, Inc. (CLYM) and Cencora (COR) have performed compared to their sector so far this year.
Aug 19, 2025 • Zacks Commentary
BULLISH
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Aug 18, 2025 • Benzinga
SOMEWHAT-BULLISH
Here's How Much $100 Invested In Cencora 5 Years Ago Would Be Worth Today - Cencora ( NYSE:COR )
Cencora COR has outperformed the market over the past 5 years by 10.59% on an annualized basis producing an average annual return of 24.24%. Currently, Cencora has a market capitalization of $56.77 billion.
Aug 18, 2025 • Benzinga
SOMEWHAT-BULLISH
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence of vision-threatening diseases The global ophthalmology drugs market, valued at US$18.34 billion in 2024, stood at ...
Aug 15, 2025 • Zacks Commentary
BULLISH
Why Cencora ( COR ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Aug 14, 2025 • Motley Fool
SOMEWHAT-BULLISH
Outlook Therapeutics Reports Q3 Revenue
Outlook Therapeutics ( NASDAQ:OTLK ) , a biopharmaceutical company focused on ophthalmic treatments, released its third quarter fiscal 2025 results on August 14, 2025. The company posted its first-ever commercial revenue from European sales of LYTENAVA ( bevacizumab gamma ) , reaching $1.5 ...